Huge thank you to David Vauzour at UEA for quantifying pCS in patient samples, and colleagues from The William Harvey Research Institute for providing us with patient samples.

Systems-level microbiome research only works when it's collaborative.
Patients with chronic kidney disease (CKD) are more prone to brain bleeds and stroke than the general population. We think that use of EGFR inhibitors (already used clinically) in these patients could protect them from some of the neuro effects of CKD.

Translational gut-brain axis work. :)

Comments